| INTRODUCTION
Several large community studies using either self-reported diagnoses or registers have shown a higher prevalence and incidence of somatic conditions in people with epilepsy than in the general population. [1] [2] [3] [4] [5] [6] [7] [8] Comorbidities, defined classically as "any additional distinct clinical entity" 9 from epilepsy, were found to be increased globally, affecting the majority of conditions assessed in each study. There is evidence that this increased prevalence is not fully explained by over-representation of unfavourable socio-economic factors among people with epilepsy 10 or reporting bias caused by greater contact with medical services. 8 Several lines of evidence also confirm that, when excluding epilepsyrelated health issues, people with epilepsy have a worse health status than people in the general population. People with epilepsy have a greater utilization of healthcare services for comorbid conditions, 11 incur higher healthcare costs than the general population after excluding epilepsy-related costs 12 and have increased premature mortality seemingly unrelated to epilepsy. 13 Most epidemiological studies analysing prevalence of comorbidities are confounded by causal (some comorbidities may be the cause of epilepsy) and resultant (comorbidities may be the consequence of epilepsy or its treatment) associations, 14 lacking data on the temporal course of the conditions. These biases do not seem, however, to explain the increased burden of comorbidities; people with epilepsy were shown to be more likely to die prematurely due to cerebrovascular disease, even those without a stroke before epilepsy onset 15 and regardless of treatment exposure. 7 Very little is known about the mechanism(s) underlying the increased burden of somatic comorbidities in epilepsy. Migraine with aura, for instance, was shown to have a bidirectional association (migraine with aura increasing the risk of developing epilepsy and vice versa), 16, 17 suggesting common underlying risk factors. 18 Better understanding of the mechanisms of comorbidities could help to prevent morbidity and premature mortality in people with epilepsy.
We assessed the prevalence and predictors of comorbid conditions in widely different settings, accounting for the whole spectrum of epilepsy, to generate explanatory hypotheses for the increased burden of somatic comorbidities in epilepsy. In contrast to previous studies on comorbidities, availability of medical assessment allowed us to minimize biases due to causes, results and treatment of epilepsy, so identifying genuine comorbidities.
| METHODS
We recorded all current and previous medical and psychiatric diagnoses distinct from epilepsy in two different adult populations with epilepsy:
people seen at a referral centre and people in the community. People seen at the referral centre were included as part of an audit of all peo- by general practitioners or self-reported by the individual; psychiatric comorbidities were reassessed if needed at the referral centre. At the referral centre, somatic conditions were not specifically re-evaluated unless part of the investigation of epilepsy. Demographic data and epilepsy characteristics were recorded in both cohorts. Family history of epilepsy and seizure types were also documented in the tertiary centre cohort based on descriptions and, when available, on observation and recording. Family history was considered as positive when more than one member of the family (genetically related) has/had seizures. Location of the seizure onset zone in the cohort assessed at the referral centre was documented, defined where possible through a combination of seizure semiology and EEG recordings. All anti-epileptic medications to which the person had been exposed were recorded in both populations; AEDs were also classified according to whether they significantly induce liver enzymes (phenobarbital, phenytoin, carbamazepine) or not. 20 The total dose of AEDs to which each person had been exposed was not available;
we used the number of AEDs over the duration of the epilepsy censored at assessment as a surrogate. Traumatic brain lesions that were presumed not to be the cause of the individual's epilepsy, and conditions that were clearly the direct exclusive consequence of traumatic lesions, were not considered as comorbidities. Indirect consequences of traumatic lesions Chi-squared and Mann-Whitney tests were used for univariable analysis of predictors of the numbers of comorbidity categories.
Multivariable stepwise backward ordinal logistic regression was used to analyse the factors influencing the number of systems (none, one, or two or more) affected by comorbidities. P values of <.05 were considered statistically significant overall, and variables with univariable P value <.1 were included in multivariable regression. Assumptions (proportionality of odds ratios, co-linearity) were checked.
We sought to adjust for age and found an interaction between age and comorbidities in the community cohort, and so the analysis was stratified with a division at 60 years. There was no interaction in the referral centre cohort (the cohort was younger on average), so a simple regression adjustment for age was used (implemented as [age-mean age] 2 ).
Multivariable logistic regression was then used to assess the effect of each identified predictor on specific comorbidity categories (yes/no) adjusting for factors found significant in the previous analyses. For the analysis of predictors of specific comorbidity categories, we performed a Bonferroni correction for multiple testing. Statistical analyses were performed with SPSS (v20; SPSS inc) and Stata (v13; Statacorp Inc.).
The study was approved by the institutional Ethics Committee.
| RESULTS
We collected data from general practices for 1278 people diagnosed with epilepsy, and from the referral centre for 2016 people with chronic epilepsy assessed there. Demographic and clinical data for both cohorts are presented in Table 1 . At the time of assessment, all people at the referral centre had active epilepsy, while 87% of the community cohort had not experienced seizures for at least 1 year. Those at the referral centre had been exposed to a greater number of AEDs than those in the community. Among people at the referral centre, 37% (750) had temporal lobe epilepsy, 17% (352) frontal epilepsy, 16% (323) multifocal or generalized epilepsy, 0.8% (16) occipital epilepsy and 0.7% (15) parietal epilepsy; the seizure onset zone could not be determined in all others.
All conditions considered as comorbid can be found in Data S1.
People at the referral centre significantly more often had somatic Figure 1 .
| Predictors of the burden of comorbidity
Factors associated with the overall burden of comorbidities are detailed in Table 2 for each cohort. Multivariable analyses in both cohorts showed that longer epilepsy duration and presence of an underlying brain lesion were independently associated with a reduced burden of somatic comorbidities, independently of age (Table 2 ). In the referral centre, female gender was a significant risk factor for a greater burden. The presence of psychiatric comorbidities was not a significant predictor of the burden of somatic comorbidities for either cohort, neither was localization of the seizure onset zone in the referral centre cohort, nor seizures in the year preceding the assessment in the community cohort. The number of AEDs to which individuals were exposed was not a significant predictor of the number comorbidity categories, but the total number of AEDs or of enzyme-inducing AEDs to which people had ever been exposed were significantly correlated with epilepsy duration in both cohorts.
Predictors of specific comorbidity categories are detailed in Table 3 .
| DISCUSSION
Our study shows that every second person with epilepsy seen at a referral centre and every third in the community has at least one somatic comorbid condition, disregarding causes of epilepsy and direct consequences of its treatment. In the only previous study considering all comorbidities, 4 the prevalence of all comorbidities was increased 1.5-fold in people with epilepsy, which is similar to our results compared with general population studies using similar methodology.
23,24
Comorbidities can indeed be classified as causing epilepsy, resulting from epilepsy or its treatment, and those with no obvious association. epilepsy, may allow us, however, to explore whether epilepsy has wider implications than commonly thought, which may explain the treatment and cause independent premature mortality found in this condition. 13 We intended to draw out mechanistic hypotheses from the epidemiological relationship between epilepsy and comorbidities, as finding predictors of the burden of somatic comorbidities would provide insight into the co-occurrence of epilepsy and other somatic conditions. This was impossible in previous studies [1] [2] [3] [4] [5] [6] [7] [8] given the limited data available on the conditions reported and epilepsy in the registries or questionnaires.
The two populations we assessed to explore the spectrum of epilepsy differed widely, in terms of the proportion of people in remission and the number of AEDs to which people were exposed. The prevalence of somatic comorbidities was significantly higher in the cohort of people seen at the referral centre, despite their younger age. The prevalence of comorbidities was not, however, assessed in exactly the same way in both cohorts (people in the community were followed in general practice in the long term without any formal reassessment, while those at the referral centre were actively reassessed), but we aimed to reduce bias by discarding conditions potentially not reported consistently. A greater prevalence of ECG abnormalities, 26 of obesity 27 and a higher mortality rate due to cancer 28 have been already reported in people with drug-resistant epilepsy: greater exposure to anti-epileptic medication has been hypothesized as the explanation. In our study, the influence of AEDs was assessed F I G U R E 1 Distribution of somatic comorbidities in both cohorts. Dark grey columns represent the referral centre cohort, light grey column the community cohort. Each comorbidity category distribution was analysed using chi-square test (or Fisher's test as needed)
as a global effect, and did not account for the role of specific AEDs in particular conditions (such as polycystic ovary syndrome). Treatment burden was correlated with epilepsy duration and was not an independent predictor. This is in line with a lifelong follow-up study 29 where the major determinant of premature mortality due to comorbidities was seizure frequency in people that had similar treatment exposure. We hypothesize T A B L E 2 Predictive factors of the number of comorbidity categories (ICD 10 Chapters), adjusted for age. To satisfy the proportionality of odds ratios assumption, the community cohort was split into two age groups (60 y and less, or more than 60 y) and age-squared was used to adjust the analysis in the referral centre cohort. Results are adjusted for all other predictors identified in the multivariable analysis (ie epilepsy duration, absence of underlying cause and age in the community cohort; gender, epilepsy duration, presence of underlying cause and age square in the referral centre cohort). Only comorbidity categories remaining significant after correction for multiple testing are listed here.
T A B L E 3 Predictors of specific comorbidity categories
that the difference between the two cohorts suggests that greater seizure frequency, rather than treatment exposure, could be the major determinant of the association of comorbidities with greater epilepsy severity.
Many common chronic conditions, such as inflammatory conditions, 30 asthma, 31 diabetes and obesity 32 are associated with significantly increased burdens of cardiovascular conditions and cancers compared with the general population. Disease severity in those conditions also seems to be a predictor of the occurrence of comorbidities, 33 which are widely considered as the consequence of low-grade chronic systemic inflammation. 34, 35 It is increasingly clear that epilepsy, mostly probably as a consequence of seizures, induces a systemic inflammatory response in the long term. 36 Several clinical studies showed that there is a plasma peak of pro-inflammatory interleukin 6 after seizures [36] [37] [38] [39] [40] [41] lasting up to 72 hours. 42 Those changes were also found interictally in people with chronic epilepsy. 36, 43 Other pro-inflammatory changes, such as increased interleukin 1β (IL-1β) or tumour necrosis factor α (TNF-α) or decreased interleukin 1 receptor antagonist (IL1ra) have been shown less consistently. [37] [38] [39] [40] A recent study 44 found significantly higher levels of interleukin 17 (IL-17), interferon γ (IFNγ), IL-1β, interleukin 6 (IL-6) in people with epilepsy than in healthy controls. Recently, C-reactive protein (CRP) was also shown to be increased post-ictally in people with epilepsy in comparison with healthy controls. 45 These cytokines are associated with the development of a wide range of somatic conditions. Increased serum IL-6 levels were shown to be an independent cardiovascular risk factor. 46, 47 In healthy people, increased IL-6 was shown independently to predict the occurrence of other cardiovascular risk factors of myocardial infarction 48 and diabetes type 2. 49 In people with previous myocardial infarction, it independently predicts the occurrence of congestive heart failure 50 and cardiovascular deaths. 51 Increased CRP level was found to predict the occurrence of several cancer types (ovarian, 52, 53 colorectal, 54 or lung cancer Shorter epilepsy duration, independently from age, was a rather counterintuitive predictor of a greater burden of somatic comorbidity categories such as circulatory conditions, suggesting that the early period after epilepsy onset is one of particular risk, which is in line with a previous study. 6 Early referral because of associated comorbidities seems unlikely, as the same effect was seen in the community cohort where people were routinely followed. A possible hypothesis would be that people with a greater burden of comorbidities early in the course of epilepsy may die prematurely and thus not be seen later. This is also in keeping with a study 29 showing increased premature mortality due to comorbidities early in the course of the disease in people with the greatest seizure frequency.
In the referral centre cohort, being female was a predictor of a higher burden of somatic conditions, affecting endocrine/metabolic/ nutritional and musculoskeletal conditions. This probably relates to females being at risk of osteoporosis 57 or of gender-specific conditions such as polycystic ovary syndrome 58 in combination with the increased probability of exposure to AEDs such as valproate in the large number of drugs tried (our model did not take into account specific conditions combined with exposure to specific medication).
The presence of an underlying lesion (structural epilepsy) was found to protect against a spectrum of somatic comorbidities in both cohorts. People without a clear cause may have been more thoroughly assessed at the referral centre and more concurrent diagnoses may have been reported in discharge summaries to maximize reimbursement, but this seems unlikely as comorbidities were systemically recorded during admission before investigation results were known. A study in people with epilepsy without an identified structural cause found significantly larger chromosomal deletions, encompassing significantly more genes, than in a group of healthy controls group. 59 It could be hypothesized that people with non-structural epilepsy (a measure limited by varying imaging qualities in our study) might have a stronger genetic contribution to the epilepsy, making them potentially more liable to harbour more somatic conditions.
Somatic comorbidities are commonly overlooked, possibly because of their heterogeneity, the presumed influence of AEDs, or because somatic comorbidities are not felt to be related to epilepsy.
Our results, suggesting a consistent link between seemingly unrelated somatic conditions and epilepsy (although they do not demonstrate it), are further evidence that epilepsy has wide physiological implications even in people with apparently mild epilepsy. Seizures, or their treatment, cannot fully explain the burden of somatic conditions, as people with mostly controlled epilepsy were also shown to have a significant premature mortality due to comorbidities, 13 independently from AED treatment. 7 Effects of epileptic syndromes (especially epilepsy without structural abnormalities or "cryptogenic" epilepsy) should therefore be considered as not limited to the central nervous system, and the overall health of people with epilepsy (including those with controlled seizures) should be carefully evaluated. General health of people with epilepsy should not be considered as unrelated to the disease and should also be a concern for the treating specialist.
Our study has several limitations. People in the community did not undergo a comprehensive assessment and, for example, the prevalence of idiopathic generalized epilepsy (genetic generalized epilepsy) and underlying structural lesions were probably underestimated, overemphasizing the proportion of people with epilepsy of unknown origin in the community. The assessment of comorbid conditions is also limited by the use of medical records; we did not directly assess somatic comorbidities using diagnostic tests. The retrospective design may bias the results through the varying degree of attention paid by the caring physicians. The cohorts were also not fully contemporary, and both sets of data were collected over a decade; secular lifestyle changes may have been confounders over that period, although the predictors found seem unlikely to have been influenced by environmental factors over that time period. Finally, the low pseudo R 2 of the multivariable analyses suggest that our model predicted only a small part of the variation of the burden of somatic comorbidities; socio-economic factors, ethnicity, lifestyle and educational level (which were not available systematically in records) would probably also have explained part of the variation. 10 Ageing is obvious also a major determinant of the burden of comorbidities; our analyses showed however that the associations described were age independent.
| CONCLUSIONS
Somatic comorbidities are very common in people with epilepsy and do not occur randomly in relation to the epilepsy. Epilepsy severity is a risk factor. The increased burden of somatic comorbidities in people without a clear underlying brain lesion could suggest a genetic predisposition for the co-occurrence of epilepsy and somatic comorbidities. Independently from age, the early period after epilepsy onset appears to be at particular risk, possibly because comorbid conditions lead to premature mortality. Epilepsy should be considered as a systemic condition not limited to the CNS. Other somatic conditions should not be considered as completely unrelated to the disease and should also be a concern for the treating specialist. 
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